Autolus Therapeutics presents data from CATULUS Phase 1 trial of obe-cel

Autolus Therapeutics (AUTL) announces presentation of preliminary data from the CATULUS Phase 1 trial of obe-cel in pediatric relapsed or refractory B-ALL patients, as well as further insights from the registrational FELIX study in adult r/r B-ALL, at the American Society of Hematology Annual Meeting. Key data: Obe-cel demonstrates high remission rates in pediatric patients with high-risk r/r B-ALL with overall response rate of 95.5%; low rates of high-grade cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome observed, consistent with obe-cel’s adult safety profile; FELIX study data analyses highlight product cell phenotype and level of CAR T persistence at three months as potential predictors of long-term remission; Real-world data independently collected by the ROCCA consortium during the US commercial launch of obe-cel were presented and show a high response rate and low levels of high-grade CRS and ICANS consistent with the clinical trial experience in the FELIX study